Antibody–drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation

作者：Solange Peters, May‐Lucie Meyer, F. André, Guillem Argilés, Alexander A. Azizi, S. Banerjee, S. Burgers, Giuseppe Curigliano, J.Z. Drago, E. Fontana, Edward B. Garon, Niklas Klümper, L. Le Bescond, Fernando López‐Ríos, Giannis Mountzios, Antonio Passaro, L. Paz-Ares, Barbara Pistilli, T. Powles, N. Reguart, Jordi Remón, Tobias Schmelzle, Mj. Skynner, Elizabeth Smyth, E. Smyth, C. Swanton, Eric Van Cutsem, S. Loi, Rolf A. Stahel · 发表于：ESMO Open · 年份：2026 · DOI：10.1016/j.esmoop.2026.108316 · 研究领域：HER2/EGFR in Cancer Research、Radiopharmaceutical Chemistry and Applications、Monoclonal and Polyclonal Antibodies Research

The European Thoracic Oncology Platform (ETOP) International Breast Cancer Study Group (IBCSG) Partners Foundation initiated a series of workshops for experts to review current evidence and offer recommendations to guide future antibody-drug conjugate (ADC) research. Here, we summarise key findings from the third workshop, which included experts in various solid tumours, basic/translational research scientists and pharmaceutical industry representatives. Recent positive phase III trial data have further incorporated ADCs into the standard of care [e.g. lung: sacituzumab tirumotecan; breast: trastuzumab deruxtecan (T-DXd), sacituzumab govitecan, datopotamab deruxtecan; muscle-invasive bladder cancer: enfortumab vedotin; ovarian cancer: mirvetuximab soravastine; cervical cancer: tisotumab vedotin]. Thus, research priorities must be tailored according to tumour type, potentially focussing initially on settings where ADCs could replace chemotherapy. Many phase III ADC trials have been initiated based on positive phase I data and although these trials are larger than those conducted historically, prespecified criteria (e.g. patient numbers and magnitude of efficacy) should be met to justify proceeding directly to phase III. Importantly, although several ADCs have been successfully developed without mandatory biomarker selection, biomarker-driven ADC development enables rational patient selection, as illustrated by multiple ADCs (e.g. T-DXd, mirvetuximab soravtansine and telisotuzu...